Sustained-release local anesthetics: advances in drug delivery systems for prolonged postoperative analgesia Authors: Seok Kyeong Oh, Sang Hyun Hong, Jung-Woo Shim Published: 2026 ABSTRACT Effective perioperative pain control is essential for patient comfort and for optimizing surgical outcomes and the quality of recovery. Multimodal analgesic strategies have become a cornerstone of modern perioperative pain management. Although regional analgesia is widely used within this framework, the clinical utility of conventional local anesthetics remains limited by their relatively short duration of action. Continuous infusion techniques can sustain local anesthetic delivery; however, catheter-based systems have several device- and technique-related limitations. In response, sustained-release local anesthetic formulations have been developed to extend analgesia after a single administration. These formulations include liposomal preparations, polymer-based delivery systems, and hydrogel-based carriers. Liposomal bupivacaine uses a multivesicular delivery system that acts as a local drug depot and gradually releases the anesthetic at the injection site. Polymer-based systems that combine local anesthetics with anti-inflammatory agents enhance analgesia by modulating the local tissue environment. Hydrogel-based carriers, including thermoresponsive and hyaluronic acid-based platforms, provide sustained drug release through three-dimensional polymer networks while minimizing systemic exposure. Recent advances in these delivery platforms have expanded the clinical potential of sustained-release local anesthetic technologies. Nevertheless, widespread clinical adoption remains constrained by several challenges, including burst release, variability in release kinetics, high costs, and limited clinical evidence. Sustained-release local anesthetic systems may provide catheter-free, prolonged postoperative analgesia in accordance with the principles of enhanced recovery after surgery. As drug delivery technologies continue to evolve, sustained-release local anesthetic formulations are likely to play an increasingly important role in perioperative pain management. INTRODUCTION Despite substantial advances in anesthetic and analgesic techniques, postoperative pain remains one of the most common and clinically significant challenges in perioperative care [1]. Inadequately controlled postoperative pain is associated with delayed mobilization, longer hospital stays, increased healthcare utilization, patient dissatisfaction, and an increased risk of persistent postsurgical pain [2,3]. Effective pain control is therefore important not only for patient comfort but also as a critical determinant of overall surgical outcomes and recovery trajectories. Opioids have traditionally been the mainstay of postoperative analgesia because of their potent and reliable analgesic effects across a wide range of surgical procedures [4]. However, opioid-based analgesia is associated with well-recognized adverse effects, including nausea, vomiting, ileus, urinary retention, sedation, and respiratory depression. Moreover, excessive perioperative opioid exposure has been linked to opioid dependence and contributes to the broader public health burden associated with opioid use [5,6]. Growing awareness of opioid-related adverse events and the broader societal effects of opioid use has intensified interest in opioid-sparing analgesic strategies [6]. A multimodal analgesic strategy has become a cornerstone of modern perioperative pain management, combining different classes of analgesics and techniques to improve pain control while minimizing opioid consumption. Within this framework, regional anesthesia plays a central role by providing targeted, site-specific analgesia and supporting enhanced recovery after surgery (ERAS) pathways [7]. Despite the widespread use of regional anesthesia, the clinical utility of conventional local anesthetics remains limited by their relatively short duration of action. Their analgesic effects therefore often fail to match the time course of postoperative pain, which typically extends beyond the immediate postoperative period. This limitation has prompted the development of strategies to prolong analgesia after a single administration and has led to the emergence of sustained-release local anesthetic systems [8]. This review examines the pharmacologic principles underlying sustained-release local anesthetics, currently available and emerging delivery platforms, and the clinical evidence supporting their use in perioperative pain management. Particular attention is given to their potential relevance within ERAS programs, in which prolonged analgesia, opioid minimization, simplified postoperative care, and early mobilization are highly desirable goals. LITERATURE SEARCH This narrative review was based on a search of PubMed, Embase, and Google Scholar for English-language articles published through 2025. Search terms included combinations of sustained-release local anesthetics, liposomal bupivacaine, polymer-based drug delivery, hydrogel, controlled release, and postoperative analgesia. Original research articles, clinical studies, preclinical investigations, and relevant reviews were selected according to their relevance to sustained-release local anesthetic formulations, drug delivery mechanisms, and clinical applications. Additional references were identified by screening the reference lists of the selected articles. LIMITATIONS OF CONVENTIONAL LOCAL ANESTHETICS The principal limitation of conventional local anesthetics is their relatively short duration of action. Widely used agents such as lidocaine, bupivacaine, and ropivacaine have distinct pharmacokinetic and pharmacodynamic profiles and therefore provide varying durations of analgesia and anesthesia [9,10]. Lidocaine, an intermediate-acting agent, typically provides analgesia for approximately 1–3 h, whereas long-acting agents such as bupivacaine and ropivacaine may extend analgesia to approximately 6–12 h after a single administration [9]. Under optimal conditions, depending on the dose, concentration, injection site, and use of adjuncts, sensory blockade may persist for up to 12 h, and complete anesthetic effects may last approximately 18–24 h in selected cases [10]. However, these prolonged effects are not consistently achieved in routine clinical practice and vary considerably among patients and procedures. Although such durations may be sufficient for minor procedures, they are often inadequate after major surgery, when pain intensity commonly peaks within the first 24–72 h [1]. Simply increasing the local anesthetic dose is not a feasible means of overcoming the limited duration of single-injection techniques, primarily because of safety concerns, particularly the risk of systemic toxicity. Strategies to prolong block duration have therefore focused on adjunctive agents rather than dose escalation alone. Adjuncts have been used to prolong single-injection blocks. Examples include epinephrine, which reduces systemic absorption, and perineural dexamethasone, which has been shown to extend block duration [9,10]. However, the magnitude and consistency of these benefits vary, and use of these agents may be limited by safety concerns, off-label administration, and heterogeneity in clinical response. Consequently, single-injection techniques alone often fail to provide sustained analgesia throughout the critical postoperative period. To overcome the limited duration of single-injection local anesthetics, continuous infusion techniques, such as continuous perineural nerve blocks and wound-infusion catheter systems, have been widely adopted in clinical practice [11]. These approaches enable sustained, titratable delivery of local anesthetics, thereby prolonging analgesia and reducing systemic opioid requirements. Their effectiveness, however, depends on proper catheter placement, secure fixation, and uninterrupted drug delivery. In practice, catheter-based systems are vulnerable to several device- and technique-related limitations. Mechanical problems, including catheter dislodgment and pump malfunction, can interrupt infusion and result in inadequate or inconsistent analgesia [12,13]. Uneven or unpredictable drug distribution, particularly with wound-infusion systems or suboptimally positioned perineural catheters, may further increase variability in analgesic outcomes [14]. An indwelling catheter also introduces a risk of infection, particularly during prolonged use [15]. Furthermore, infusion pumps, dedicated disposable supplies, and ongoing monitoring increase healthcare costs and create additional logistical burdens for both clinicians and patients. These requirements may limit the feasibility of continuous infusion strategies in ambulatory or resource-constrained settings. These limitations are particularly relevant to ERAS protocols. ERAS pathways emphasize early mobilization, reduced use of invasive devices, and simplified postoperative management to facilitate faster recovery and shorter hospital stays [7]. Indwelling catheter systems may conflict with these goals because they can restrict mobility, require ongoing monitoring, and necessitate timely removal. Conversely, early catheter removal may shorten the duration of effective analgesia and increase reliance on systemic opioids. Collectively, these challenges highlight the need for alternative analgesic strategies that provide prolonged, reliable, and catheter-free pain control. Sustained-release local anesthetic systems have therefore emerged as a promising approach to addressing this gap in perioperative pain management. SUSTAINED DRUG DELIVERY SYSTEMS FOR LOCAL ANESTHETICS Recent advances in pharmaceutical formulation and biomaterials science have led to novel drug delivery systems designed to prolong the effects of local anesthetics [16]. A central concept in sustained-release drug delivery is the formation of a localized drug depot at the administration site [17]. In these systems, the active drug is incorporated into a carrier matrix, such as liposomes, biodegradable polymers, or hydrogel networks. After administration, the carrier retains the drug in the surrounding tissue and releases it gradually through platform-specific mechanisms, including diffusion across lipid membranes, matrix degradation, and diffusion-controlled release [18]. This depot-based mechanism prolongs the exposure of nearby neural structures to local anesthetics while reducing rapid systemic absorption. By regulating drug diffusion and release kinetics, advanced delivery systems aim to extend analgesia beyond what is achievable with conventional formulations [17]. These technologies may provide prolonged postoperative pain control after a single administration, potentially reducing the need for continuous catheter-based techniques. Several sustained-release platforms have therefore been developed and investigated for perioperative analgesia, including liposomal formulations, polymer-based delivery systems, and hydrogel-based carriers. LIPOSOMAL FORMULATIONS Liposomes are spherical vesicles composed of phospholipid bilayers that can encapsulate both hydrophilic and lipophilic drugs, thereby enabling controlled, localized drug delivery [19]. Since liposomes were first described in the 1960s, liposomal formulations have been widely investigated as drug carriers because they can improve pharmacokinetic profiles, reduce systemic toxicity, and prolong drug release at the target site. In regional anesthesia and postoperative pain management, liposomal formulations serve as local drug depots that gradually release anesthetic agents at the injection site, thereby prolonging analgesia while limiting systemic exposure [20]. Among these formulations, liposomal bupivacaine (Exparel®, Pacira BioSciences) is an extended-release local anesthetic developed to provide prolonged postoperative analgesia. As shown in Fig. 1, it uses a multivesicular liposomal delivery system in which bupivacaine is encapsulated within multiple lipid chambers [21]. After administration, bupivacaine is gradually released as the lipid membranes degrade, allowing sustained analgesic effects for up to 72 h [22]. By serving as a localized drug depot, liposomal bupivacaine is intended to prolong postoperative analgesia without continuous infusion devices. Liposomal bupivacaine has been studied most extensively for surgical wound infiltration. In this setting, several randomized controlled trials have demonstrated its efficacy as an extended-release local anesthetic, and it has subsequently been incorporated into clinical practice for surgical site infiltration [23,24]. However, these pivotal trials should be interpreted cautiously. Although the primary analyses showed significant reductions in cumulative pain scores, subsequent evaluations suggested that clinically meaningful differences were largely confined to the first 24 postoperative hours. Systematic reviews have also questioned the consistency of these findings because of substantial heterogeneity in study quality and clinical outcomes [20,25]. Many positive placebo-controlled trials were considered to have a relatively high risk of bias [23,24,26], whereas several randomized trials with a lower risk of bias found no significant analgesic benefit [27]. Liposomal bupivacaine has also been evaluated for periarticular injection in total knee arthroplasty (TKA) [28,29]. Some studies reported improved postoperative pain scores and reduced opioid consumption compared with conventional local anesthetics. However, a subsequent multicenter randomized trial found no superior analgesic efficacy relative to periarticular infiltration with conventional bupivacaine hydrochloride, underscoring the inconsistency of the available clinical evidence [30]. More recently, liposomal bupivacaine has been investigated in regional anesthesia. Randomized clinical trials have evaluated its use in peripheral nerve blocks, including adductor canal blocks for knee surgery, fascia iliaca blocks for hip surgery, transversus abdominis plane blocks for abdominal surgery, and brachial plexus blocks for shoulder procedures. Several trials reported improved early postoperative analgesia relative to conventional long-acting local anesthetics in some clinical settings [31-33], whereas others found no superior efficacy with perineural administration [34,35]. Subsequent systematic reviews and meta-analyses indicate that the overall clinical benefits remain inconsistent and that any analgesic advantage is likely to be modest and procedure-specific [36,37]. Representative clinical studies of liposomal bupivacaine for postoperative analgesia are summarized in Table 1. Based on evidence from pivotal randomized controlled trials, liposomal bupivacaine was approved by the U.S. Food and Drug Administration (FDA) in 2011 for surgical site infiltration to provide prolonged postoperative analgesia [38]. In 2018, the FDA expanded its indication to include interscalene brachial plexus block. The formulation was subsequently approved in Europe in 2020 for surgical site infiltration, brachial plexus block, and femoral nerve block [38]. In 2023, the FDA further expanded its indications to include sciatic nerve block in the popliteal fossa and adductor canal block in adults [37]. However, systematic reviews have not consistently demonstrated superior analgesic efficacy over conventional local anesthetics, reflecting substantial heterogeneity among surgical procedures, analgesic techniques, and study designs [20,25,37]. Collectively, these findings suggest that liposomal bupivacaine has a more established role in wound infiltration, whereas perineural use remains an evolving application with potentially selective benefits in certain clinical settings. Although efficacy varies by surgical procedure and block technique, liposomal bupivacaine remains the most extensively studied and widely available sustained-release local anesthetic formulation. POLYMER-BASED DELIVERY SYSTEMS Polymer-based systems have long been investigated for the controlled and prolonged release of therapeutic agents. Studies conducted in the 1970s and 1980s showed that biodegradable polymer matrices could regulate drug diffusion and degradation kinetics, enabling sustained drug release at the target site [39]. Subsequent advances in polymer chemistry enabled the application of these systems to perioperative analgesia, in which incorporating local anesthetics into polymer matrices can create localized depots that provide prolonged analgesia [40]. HTX-011 (Zynrelef®, Heron Therapeutics) is a polymer-based extended-release formulation containing bupivacaine and meloxicam within a biodegradable polymer matrix known as Biochronomer® (Heron Therapeutics) [41]. This platform enables the controlled, sustained release of both agents directly at the surgical site, providing prolonged local analgesia without continuous infusion devices. After administration, the polymer matrix undergoes gradual hydrolytic degradation, resulting in predictable drug release over an extended period, typically up to 72 h. The formulation was designed to provide a dual-action analgesic mechanism. In addition to its anti-inflammatory effects, meloxicam modulates the local tissue environment by attenuating the inflammation-associated acidosis that commonly follows surgical tissue injury [42]. Tissue injury or surgery increases local acidity, thereby reducing the penetration of local anesthetics such as bupivacaine into nerve cells (Fig. 2). Restoring a more physiologic pH increases the proportion of nonionized bupivacaine molecules, facilitating their passage across neuronal membranes and enhancing sodium channel blockade [41]. Through this mechanism, HTX-011 is designed to improve both the magnitude and duration of postoperative analgesia relative to conventional local anesthetic formulations. Preclinical studies and early clinical investigations have shown that this combination strategy can reduce inflammatory responses and provide effective analgesia for up to 72 h after surgery [42]. As summarized in Table 2, subsequent phase III randomized controlled trials in bunionectomy, herniorrhaphy, and TKA demonstrated the efficacy of HTX-011 for postoperative analgesia when administered by wound infiltration [43-45]. On the basis of these findings, the formulation received regulatory approval in the U.S. and Europe for the management of postoperative pain, providing an option for extended-duration local analgesia after surgery. Collectively, these findings demonstrate the clinical potential of polymer-based sustained-release systems and support their role in the development of prolonged local anesthetic delivery. Although the available phase III trials have demonstrated favorable efficacy, the current evidence is largely limited to wound infiltration, and the effectiveness of polymer-based sustained-release formulations in other clinical applications remains uncertain. Continued advances in biomaterial engineering may improve their versatility and broaden their clinical applications. HYDROGEL-BASED CARRIERS The concept of hydrogel materials was introduced in the 1960s with the development of poly(2-hydroxyethyl methacrylate) (pHEMA) hydrogels for biomedical applications by Wichterle and Lím [46]. Hydrogels are three-dimensional (3D) hydrophilic polymer networks formed by physical or chemical cross-linking that can absorb large amounts of water while maintaining structural integrity [47]. Their high water content creates a tissue-like microenvironment that facilitates molecular diffusion. In addition, their structural properties can be tailored by modifying the polymer composition, cross-linking density, and degradation kinetics, allowing material properties to be optimized for various biomedical applications [48]. Because of these physicochemical properties, hydrogels have emerged as promising platforms for wound healing, tissue engineering, and controlled drug delivery [49,50]. As localized drug depots, hydrogel-based delivery systems can sustain drug release while limiting systemic exposure. This potential has prompted extensive investigation of local anesthetic formulations for wound infiltration, perineural injection, and intra-articular administration [18,51]. After administration into surgical tissues, drugs may be released through diffusion from the hydrogel matrix, degradation of the polymer network or embedded polymeric carriers, or a combination of these mechanisms, thereby prolonging postoperative analgesia (Fig. 3) [18,52]. These properties make hydrogel-based systems attractive candidates for single-shot strategies intended to provide prolonged postoperative pain control. Recent development efforts have increasingly focused on injectable, stimuli-responsive hydrogel platforms that provide more predictable drug release, improved tissue retention, and greater clinical applicability [53]. Advances in polymer composition, cross-linking strategies, and hydrogel engineering are expected to further enhance the translational potential of hydrogel-based sustained-release local anesthetic systems. To achieve more precise control over drug release, stimuli-responsive hydrogels have been engineered to respond to environmental or physiological stimuli, including pH, temperature, light, and mechanical stress [54]. Among stimuli-responsive hydrogel platforms, thermoresponsive hydrogels have attracted particular interest for sustained-release local anesthetic formulations [55]. Hyaluronic acid-based hydrogels represent another promising platform because of their excellent biocompatibility, biodegradability, and capacity for localized, sustained drug release [56]. Thermoresponsive hydrogels Thermoresponsive hydrogels are a subclass of smart hydrogels that undergo reversible sol-gel phase transitions in response to changes in temperature [57]. Early investigations of temperature-sensitive polymers began in the 1970s and 1980s, particularly with studies of poly(N-isopropylacrylamide) and related polymers that demonstrated temperature-dependent phase behavior. These studies laid the foundation for the development of temperature-responsive biomaterials for drug delivery. A thermoresponsive hydrogel system (Welpass®, Dongsung Pharm.) uses poloxamer 407 as its primary carrier matrix. Poloxamer 407 is a triblock copolymer composed of hydrophilic polyethylene oxide and hydrophobic polypropylene oxide segments [58]. This amphiphilic structure enables temperature-dependent micelle formation and reversible sol-gel transitions. At low temperatures, the formulation remains liquid, facilitating injection or application to surgical tissues. After administration, body temperature induces micelle aggregation and gel formation, creating a localized hydrogel depot at the target site. The resulting gel gradually releases the incorporated local anesthetic through diffusion and polymer-matrix relaxation, thereby providing analgesia over an extended postoperative period [18,51]. In situ gel formation also helps confine the drug to the target tissue, potentially reducing systemic absorption and improving the safety profile of local anesthetic delivery. Recent advances in biodegradable thermoresponsive polymer systems have improved sustained-release characteristics and prolonged postoperative analgesia in preclinical models [59]. Poloxamer-based thermoresponsive hydrogel systems have also been investigated for postoperative pain control in several surgical settings (Table 3). Randomized controlled trials reported that a poloxamer 407-based hydrogel formulation provided postoperative analgesia that was noninferior to continuous thoracic paravertebral block after thoracoscopic pulmonary resection and to continuous wound infiltration after laparoscopic colorectal surgery [60,61]. Additional studies found that PF-72-based thermoresponsive hydrogel formulations were associated with lower postoperative pain scores after laparoscopic abdominal or orthognathic surgery [62,63]. Collectively, these preclinical and clinical findings support the continued translation of thermoresponsive hydrogel systems as promising platforms for single-shot postoperative analgesia. However, the clinical evidence remains limited by the small number of studies and the absence of multicenter randomized trials. Hyaluronic acid–based hydrogels Another emerging hydrogel platform for the sustained delivery of local anesthetics uses cross-linked hyaluronic acid matrices. Hyaluronic acid is a naturally occurring glycosaminoglycan that is widely distributed in the extracellular matrix and is known for its excellent biocompatibility, biodegradability, and water-retention capacity [64]. Since its discovery and structural characterization in the early 20th century, hyaluronic acid has been extensively studied for various biomedical applications [65]. In clinical practice, hyaluronic acid-based formulations have long been used for intra-articular viscosupplementation in osteoarthritis and as dermal fillers in aesthetic medicine [66,67]. Decades of clinical use have demonstrated favorable safety profiles and high biocompatibility, making hyaluronic acid an attractive biomaterial for drug delivery. Chemical cross-linking enables hyaluronic acid polymers to form stable 3D hydrogel networks that can encapsulate therapeutic agents and provide localized, sustained drug release [68]. Unlike thermoresponsive hydrogels, which undergo a sol-to-gel transition in response to physiological temperature after injection, hyaluronic acid hydrogels consist of preformed polymer networks that act as localized drug depots after administration [69]. This strategy may help maintain therapeutic local drug concentrations while minimizing systemic exposure. Recent experimental studies have explored the incorporation of local anesthetics into hyaluronic acid-based hydrogel matrices for sustained drug delivery [56]. An early proof-of-concept study demonstrated that in situ cross-linked hyaluronic acid hydrogels prolonged sciatic nerve blockade by providing sustained local release of bupivacaine [70]. More recently, an injectable thermosensitive cross-linked hyaluronic acid hydrogel demonstrated enhanced injectability, prolonged bupivacaine release, and extended sciatic nerve blockade, highlighting its promise as an advanced anesthetic delivery platform [71]. Collectively, these findings support the feasibility of hyaluronic acid hydrogel carriers for prolonged local anesthetic delivery. Although these preliminary studies demonstrate the feasibility of hyaluronic acid-based hydrogels for sustained local anesthetic delivery, the available evidence remains largely limited to experimental and preclinical investigations. Building on these findings, early clinical studies of cross-linked hyaluronic acid hydrogel carriers combined with local anesthetics are underway. Continued advances in hydrogel composition, cross-linking strategies, and drug incorporation technologies are expected to further optimize release characteristics and expand clinical applicability, making hyaluronic acid-based hydrogels a promising platform for next-generation sustained-release local anesthetic formulations [68]. CURRENT LIMITATIONS AND CHALLENGES Despite substantial advances in sustained-release local anesthetic technologies, several challenges may limit their widespread clinical adoption. The relatively high acquisition cost of liposomal bupivacaine (approximately U.S. $376 for a 266-mg vial) has raised concerns about its cost-effectiveness in routine clinical practice [72]. Although some studies have reported overall cost savings through reduced hospital resource utilization, the available economic evidence remains inconsistent and appears to depend on the surgical procedure and perioperative analgesic protocol [73]. Formulation-related challenges, including burst release, instability, and variability in drug diffusion profiles, may also contribute to inconsistent analgesic efficacy across procedures and block techniques [18]. Addressing these limitations will be important for optimizing the clinical value of liposomal sustained-release local anesthetic formulations. Although polymer-based sustained-release formulations such as HTX-011 have demonstrated favorable clinical efficacy, several limitations remain. Their approved use is currently limited to surgical site infiltration, and evidence for peripheral nerve block techniques is limited, with no corresponding regulatory approval. In addition, because of their controlled-release characteristics, polymer-based systems may have a slower onset of analgesia than conventional local anesthetics [43]. Formulation-specific components, such as meloxicam in HTX-011, may also preclude use in patients with contraindications to nonsteroidal anti-inflammatory drugs [74]. Continued optimization and broader clinical evaluation will be important for expanding the applications of these formulations. Hydrogel-based sustained-release systems also face several challenges. Drug release may be influenced by polymer composition, cross-linking characteristics, and the local tissue environment, potentially resulting in variable release kinetics and analgesic duration across surgical settings [75]. Currently available thermoresponsive hydrogel formulations also have substantially higher acquisition costs than conventional local anesthetic solutions, which may impede broader adoption despite promising clinical outcomes. Furthermore, hydrogel formulations are often regulated as drug-device combination products, which complicates regulatory approval. Consequently, relatively few hydrogel-based sustained-release local anesthetic formulations have been approved in major markets such as the U.S. and Europe [18]. These challenges are particularly relevant to emerging hyaluronic acid-based hydrogel formulations, for which clinical validation and regulatory approval remain limited despite encouraging preclinical findings and ongoing clinical investigations. Continued formulation optimization, rigorous clinical validation, and streamlined regulatory pathways will therefore be essential for widespread adoption. Regulatory approval and commercial availability vary substantially among regions. Liposomal bupivacaine is approved in the U.S. and Europe, whereas HTX-011 is currently approved in the U.S.; its European Union marketing authorization, granted in 2020, was withdrawn in 2023 at the manufacturer’s request for commercial reasons. In contrast, thermoresponsive hydrogel-based sustained-release local anesthetic formulations have limited regulatory approval and commercial availability outside South Korea. This regional heterogeneity may hinder broader clinical adoption and limit the generalizability of clinical experience across healthcare systems. Overall, addressing these limitations will require continued optimization of sustained-release delivery systems, robust multicenter clinical validation, and evidence of cost-effectiveness to support broader regulatory approval and adoption across healthcare systems. FUTURE PERSPECTIVES Future research is expected to advance intelligent, procedure-specific sustained-release local anesthetic systems that provide more precise control over drug release and improved tissue targeting [76]. Continued innovation in polymer chemistry, biomaterials engineering, and carrier design will facilitate the development of next-generation formulations with enhanced efficacy and safety. Combination delivery strategies, such as the co-delivery of local anesthetics with anti-inflammatory or other adjuvant agents, also represent a promising approach to optimizing postoperative analgesia [77]. Finally, well-designed multicenter clinical trials will be essential for establishing optimal dosing regimens, long-term safety, cost-effectiveness, and procedure-specific efficacy. CONCLUSION Sustained-release drug delivery systems have emerged as a promising strategy for overcoming the limitations of conventional local anesthetics in postoperative pain management. Advances in delivery technology enable more controlled and prolonged local anesthetic release, potentially extending analgesia while minimizing adverse effects. Broader clinical adoption will require continued optimization, robust clinical validation, improved cost-effectiveness, and wider regulatory approval. Personalized analgesic strategies and combination delivery systems may further improve postoperative pain control. A key advantage of sustained-release formulations is their ability to provide prolonged analgesia without catheter-based continuous infusion. This single-shot approach is closely aligned with ERAS principles, including opioid minimization, simplified postoperative care, and early mobilization. As delivery technologies continue to evolve, sustained-release local anesthetic systems are expected to play an increasingly important role in perioperative pain management.